{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:14Z","timestamp":1792144814122,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.conctc.2025.101574","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:12:47Z","timestamp":1764029567000},"page":"101574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease"],"prefix":"10.1016","volume":"48","author":[{"given":"Silvio","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"D'Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-1322","authenticated-orcid":false,"given":"Dirk","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Adsul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Oberai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10432","key":"10.1016\/j.conctc.2025.101574_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"issue":"10080","key":"10.1016\/j.conctc.2025.101574_bib2","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.conctc.2025.101574_bib3","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.conctc.2025.101574_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ibd\/izae119","article-title":"Residual disease burden among European patients with inflammatory bowel disease: a real-world survey","volume":"31","author":"Burisch","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.conctc.2025.101574_bib5","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig. Dis. Sci."},{"issue":"15","key":"10.1016\/j.conctc.2025.101574_bib6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.conctc.2025.101574_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.conctc.2025.101574_bib8","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.conctc.2025.101574_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.gastro.2021.04.068","article-title":"Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease","volume":"161","author":"Stalgis","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.conctc.2025.101574_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"4","key":"10.1016\/j.conctc.2025.101574_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.conctc.2025.101574_bib12","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.conctc.2025.101574_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/ibd\/izad224","article-title":"Vedolizumab efficacy is associated with decreased intracolonic dendritic cells, not memory T cells","volume":"30","author":"Boden","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.conctc.2025.101574_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"12","key":"10.1016\/j.conctc.2025.101574_bib15","article-title":"Upadacitinib in Crohn's disease: a comprehensive systematic review of efficacy and safety","volume":"15","author":"Wodeyar","year":"2023","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.conctc.2025.101574_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl1","key":"10.1016\/j.conctc.2025.101574_bib17","article-title":"P969 Unveiling the molecular mechanisms of the combination of vedolizumab with JAK inhibitors in Crohn\u2019s disease through a systems biology and artificial intelligence-based approach","volume":"18","author":"Mar\u00edn-Jim\u00e9nez","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.conctc.2025.101574_bib21","series-title":"Entyvio (vedolizumab) Full prescribing information, Lexington, MA, 2024","year":"2024"},{"issue":"3","key":"10.1016\/j.conctc.2025.101574_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.conctc.2025.101574_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"issue":"11","key":"10.1016\/j.conctc.2025.101574_bib24","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/ibd.22872","article-title":"Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives","volume":"18","author":"Ravikoff","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.conctc.2025.101574_bib25","article-title":"Advanced combination therapy: is it the best way to break the therapeutic ceiling?, Therap","volume":"17","author":"Wetwittayakhlang","year":"2024","journal-title":"Adv. Gastroenterol."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:52:27Z","timestamp":1773852747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865425001486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"alternative-id":["S2451865425001486"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101574","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Development Center Americas Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101574"}}